UroGen PharmaURGN
About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Employees: 203
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 20
60% more capital invested
Capital invested by funds: $419M [Q1] → $672M (+$253M) [Q2]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
15.51% more ownership
Funds ownership: 81.9% [Q1] → 97.41% (+15.51%) [Q2]
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
3% more funds holding
Funds holding: 112 [Q1] → 115 (+3) [Q2]
25% less call options, than puts
Call options by funds: $3.18M | Put options by funds: $4.24M
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
12 analyst ratings
EF Hutton Jason Kolbert 50% 1-year accuracy 43 / 86 met price target | 106%upside $25 | Buy Maintained | 6 Nov 2024 |
EF Hutton Jason Kolbert 50% 1-year accuracy 43 / 86 met price target | 106%upside $25 | Buy Maintained | 29 Oct 2024 |
EF Hutton Jason Kolbert 50% 1-year accuracy 43 / 86 met price target | 106%upside $25 | Buy Maintained | 21 Oct 2024 |
EF Hutton Jason Kolbert 50% 1-year accuracy 43 / 86 met price target | 106%upside $25 | Buy Maintained | 16 Oct 2024 |
Oppenheimer Leland Gershell 64% 1-year accuracy 39 / 61 met price target | 230%upside $40 | Outperform Reiterated | 16 Oct 2024 |
Financial journalist opinion
Based on 7 articles about URGN published over the past 30 days